Table 3.
The results of psychometric scales and side effect rating scale data analysis (scores) in patients who received fluvoxamine obtained after visit 3 (day 21 of the inpatient treatment course)
| Scale | GG | GA | P-value |
|---|---|---|---|
| SoPA | 3.000 [2.000; 3.000] | 5.000 [5.000; 7.000] | 0.000 |
| PACS | 2.000 [2.000; 2.000] | 1.000 [1.000; 2.000] | 0.015 |
| VAS | 13.000 [10.000;16.000] | 29.000 [24.000; 32.000] | 0.000 |
| CGI | 0.000 [0.000; 1.000] | 2.000 [2.000; 2.000] | 0.000 |
| HADS | 5.000 [3.000; 6.000] | 12.000 [11.000; 15.000] | 0.000 |
| HAM-D | 4.000 [2.000; 5.000] | 6.000 [6.000; 7.000] | 0.000 |
| BDI | 21.000 [13.000; 28.000] | 20.000 [18.000; 22.000] | 0.918 |
| UKU | 5.000 [1.000; 9.000] | 19.000 [18.000; 22.000] | 0.000 |
Note: Data has been presented in as median and interquartile range.
Abbreviations: BDI, Beck Depression Inventory; CGI, Clinical Global Impression; HADS, Hospital Anxiety and Depression Scale; HAM-D, Hamilton Rating Scale for Depression; PACS, Penn Alcohol Craving Scale; SoPA, Scale of Pathological Addiction; UKU, The UKU Side Effect Rating Scale; VAS, Visual Analog Scale.